GS-1101 (also called Idelalisib, CAL-101), a PI3K inhibitor specifically targeting PI3Kδ isoform [5] has been approved for chronic lymphocytic leukemia (CLL) therapy, while more PI3K inhibitors are under clinical evaluation. This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.